Peter Juul Madsen

Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA.

Roche Group manages real estate properties. The company designs, develops and constructs residential, commercial and industrial properties. It also provides property management services. The company is headquartered in Basel, Switzerland.

JenaValve Technology GmbH develops and manufactures transcatheter valve implantation systems for transapical and transfemoral implantation. The firm offers a therapeutic alternative to surgical aortic valve replacement for high-risk patients suffering from aortic heart valve stenosis. The company was founded by Markus Ferrari, Volker Guyenot and Hans-Reiner Figulla in 2006 and is headquartered in Munich, Germany.

Bausch & Lomb Australia Pty Ltd. manufactures and distributes prescription medicines. It offers consumer healthcare, prescription, aesthetic skin and eyecare. The company was founded in 2006 and is headquartered in Chatswood, Australia.

Dipylon Medical AB engages in the research and development of pharmaceutical products. The firm manufactures and sells products, materials and general medical instruments. It offers metabolic patient monitoring system. The company was founded on April 3, 1984 and is headquartered in Solna, Sweden.

Life Science Ventures provides financial advice.

FBC Device ApS provides spinal implants for the treatment of degenerative disc disease. Its products include Statur-L. The firm develops and manufactures healthcare equipment that helps in the placement of spine in correct position after an implant surgery. The company was founded by Finn Bjarke Christensen in 2005 and is headquartered in Risskov, Denmark.

Acerta Pharma BV develops drugs for oncology and autoimmune diseases. It operates as a biotech company that combines technology platforms in drug discovery and development such as the covalent technology platform and the multiparametric phosphoflow cytometry platform. The company was founded by Allard Kaptein in 2012 and is headquartered in Oss, Netherlands.

Forendo Pharma Oy provides novel pharmaceutical treatments for endometriosis and low testosterone levels. Its product fispemifene is the first selective estrogen receptor modulator designed only for men, which helps for the treatment of symptoms of low testosterone, in phase II clinical studies in men with secondary hypogonadism; fispemifene has normalized the low testosterone levels. Its 17HSD1-inhibitor focuses on endometriosis, is a potent and selective lead compounds demonstrated in vivo proof of efficacy in disease model of endometriosis. The company was founded by Risto Arvo Sakari Lammintausta in 2013 and is headquartered in Turku, Finland.

IO Biotech ApS operates as a clinical stage biotech company. It develops immunotherapy for cancer by targeting a mechanism used by tumour cells to evade immune responses. The company was founded by Mai-Britt Zocca, Mads Hald Andersen, Inge Marie Svane, Anders Ljungqvist and Per Thor Straten and is headquartered in Copenhagen, Denmark.

Acarix A/S engages in development, production and advertisement of a new cardiovascular diagnostic methods and equipment. It develops engages in the non-invasive and non-radiation acoustic detection of coronary artery disease. The firm designs CADScor, a sensor that records, processes, and displays heart signal. The company was founded in 2009 and is headquartered in Kongens Lyngby, Denmark.

Part of Sunstone Capital A/S, Sunstone Life Science Ventures A/S is a Danish company that provides investment services. The private company is based in Copenhagen, Denmark.

ReWind Therapeutics NV is a biotech company based in Leuven, Belgium that develops first-in-class remyelinating therapies for myelin-related diseases. The Belgian company's aim is to bring these therapies into fast-track clinical development. Myelin-related diseases, such as multiple sclerosis, are those where the myelin sheath surrounding nerves is damaged, leading to deficient nerve transmission that may affect multiple functions, including sensation, cognition, and movement, among others. ReWind Therapeutics develops first-in-class therapeutics designed to re-initiate the process of remyelination in patients suffering from major debilitating diseases such as multiple sclerosis, optic neuritis, or nerve injuries. The company's team has extensive R&D expertise and has built a strong patent estate for developing novel remyelination therapeutics. The company was founded in 2017 by Ku Leuven's Centre for Drug Design and Discovery (CD3) and Axxam S.p.A. The CEO of the company since 2021 is Anja Harmeier.

Parsimoneous Holding ApS functions as an investment holding Danish company. The private company is based in Gentofte, Denmark. The CEO of the company is Claus Asbjørn Andersson.

Latentix ApS provides custom computer programming services. The private company is based in Frederiksberg, Denmark.

Sunstone Tv Lsv Special LP Ill Aps is an investment holding Danish company. The private company is based in Copenhagen, Denmark. The CEO of the company is Claus Asbjørn Andersson.

Part of Sunstone Capital A/S, Sunstone LSV General Partner Ill ApS functions as an investment holding Danish company. The private company is based in Copenhagen, Denmark. The CEO of the company is Claus Asbjørn Andersson.

Abinitio ApS is an investment holding Danish company. The private company is based in Copenhagen, Denmark. The CEO of the company is Claus Asbjørn Andersson.

Sunstone Lsv General Partner Ii ApS functions as an investment holding Danish company. The private company is based in Copenhagen, Denmark.

Sunstone Lsv & Co. The private company is based in Copenhagen, Denmark. Invest Ill Holding Aps functions as an investment holding Danish company.

Kartos Therapeutics, Inc. is a clinical stage biopharmaceutical company based in Redwood City, CA. Kartos Therapeutics, Inc. is focused on developing a potential MDM2 inhibitor for the treatment of various TP53 wild-type hematological malignancies and solid tumors. The company was founded by Wayne P. Rothbaum and Iain David Dukes, and the CEO is Jesse Seton McGreivy.